Data on the outcomes of ventricular tachycardia (VT) ablation in nonischemic dilated cardiomyopathy (NIDCM) are insufficient. The Heart Center of Leipzig VT (HELP-VT) study is a large, prospectively conducted trial including >220 patients that aimed to compare outcomes after radiofrequency catheter ablation of VT in patients with NIDCM compared with ischemic cardiomyopathy. We found that even though the short-term success rates after VT ablation in NIDCM and ischemic cardiomyopathy are similar, the long-term outcomes in NIDCM were significantly worse. Substrate-guided ablation has limitations resulting from the low incidence of late potentials and endocardial scar areas. Complete VT noninducibility at the end of the ablation is associated with beneficial long-term outcome in NIDCM. Pursuing compete elimination of all inducible VTs with epicardial mapping and ablation, when necessary, may be beneficial to achieve a better longterm success in NIDCM. See p 728.
Association Between Insomnia Symptoms and Mortality: A Prospective Study of US Men
Insomnia, the most common sleep/wake disorder, is characterized by difficulty initiating sleep, difficulty maintaining sleep, early-morning awakenings, or nonrestorative sleep. Insomnia affects 10% to 30% of the general population in the United States depending on its definition. Insomnia has been thought to influence total mortality and cardiovascular mortality specifically, but results to date have been inconsistent. Thus, we prospectively examined the association between insomnia symptoms and all-cause and cause-specific mortality in 23 447 men participating the Health Professionals Follow-Up Study (HPFS), a well-characterized US ongoing cohort. We found that difficulty initiating asleep and nonrestorative sleep, but not difficulty maintaining sleep or early-morning wakeup, were associated with a modestly higher risk of total mortality and cardiovascular mortality. The increased risk was independent of a variety of risk factors for mortality, including lifestyle factors and presence of several medical morbidities. These observations were supported by our concurrent meta-analysis, including results of the present study and 9 previously published studies on this topic. Although future studies are still needed before a firm conclusion can be reached, our study provides additional evidence that insomnia symptoms may be an important modifiable risk factor affecting longevity. See p 737.
Aneurysm Global Epidemiology Study: Public Health Measures Can Further Reduce Abdominal Aortic Aneurysm Mortality
This study provides robust evidence that abdominal aortic aneurysm mortality is not declining globally as has previously been suggested and that a linear relationship exists between trends in abdominal aortic aneurysm mortality and trends in systolic blood pressure, cholesterol, smoking prevalence, and body mass index. A novel obesity paradox has been identified that suggests a survival benefit for abdominal aortic aneurysm patients with an elevated body mass index; however, this requires further investigation. The importance of these findings is that public health measures to address common cardiovascular risk factors could further reduce abdominal aortic aneurysm mortality globally, and these benefits appear to be greatest in the younger age group. See p 747.
Racial/Ethnic and Gender Gaps in the Use of and Adherence to Evidence-Based Preventive Therapies Among Elderly Medicare Part D Beneficiaries After Acute Myocardial Infarction
Mortality in acute myocardial infarction has declined considerably in recent decades as a result of improvements in care and use of evidence-based preventive therapies. However, racial/ethnic and gender disparities in outcomes persist. This study examined both the initial use within 30 days and the 12-month medication adherence to β-blockers, angiotensinconverting enzyme inhibitors/angiotensin receptor blockers, and statins among a cohort of 85 017 Medicare Part D beneficiaries after hospital discharge for acute myocardial infarction. Racial/ethnic and gender gaps in the initial use of the 3 preventive therapies after discharge were not evident. However, the study showed significant racial and gender gaps in adherence to these preventive therapies in the 12 months after discharge. Compared with white patients, black and Hispanic patients had significantly lower medication adherence, and minority women had additionally decreased medication adherence. The results suggest that clinicians need to be cognizant of the importance of medication adherence after acute myocardial infarction among minorities (particularly minority women). Beyond the efforts in prescribing evidence-based therapies at discharge, which seem to have largely decreased gaps among demographic subgroups, there is a need to strengthen care and services related to long-term medication adherence among minority patients and especially minority women. There is also a need for national programs to extend efforts on post-acute myocardial infarction care to the outpatient setting, where the Get With The Guidelines program has only recently begun expanding. Continuity of care and collaboration between healthcare providers in institutional and community settings with an emphasis on patient adherence to evidence-based therapies after acute myocardial infarction may help mitigate outcome disparities. See p 754.
Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis
This is the second phase III trial with the oral thrombin inhibitor dabigatran for the treatment of acute venous thromboembolism for 6 months. The results of this trial are presented, Volume 129 ◼ Number 7 ◼ February 18, 2014
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February 18, 2014 together with a pooled analysis of both studies. Dabigatran was given at a dose of 150 mg twice daily with no dose adjustments. Patients with a creatinine clearance <30 mL/min were excluded. Because both trials used initial parenteral anticoagulation also in the dabigatran treatment arm, this drug should not be used as monotherapy for acute venous thromboembolism. The similar efficacies of dabigatran and standard treatment with warfarin were confirmed. Bleeding was analyzed as major bleeding, major or clinically relevant nonmajor bleeding, and any bleeding. For the last 2 categories, the risk was significantly reduced in the dabigatran group in both studies. Major bleeding was not significantly reduced in any of the trials separately or pooled when the entire treatment period was included. For the treatment period on oral drug only, that is, after the initial week with parenteral therapy but without dabigatran, there was also in the pooled analysis a borderline significant reduction of major bleeds. Deaths, adverse events, and acute coronary syndromes were similar in both groups. The pattern of lower risk of bleeding is seen with all new anticoagulants compared with vitamin K antagonists. Furthermore, here, as in other studies with the new anticoagulants in venous thromboembolism or in atrial fibrillation, there is a consistent trend to lower the risk of intracranial bleeding. See p 764.
Synergistic Role of Protein Phosphatase Inhibitor 1 and Sarco/Endoplasmic Reticulum Ca 2+ -ATPase in the Acquisition of the Contractile Phenotype of Arterial Smooth Muscle Cells
Phenotypic switching of vascular smooth muscle cells (VSMCs) from a contractile/quiescent to a proliferative/ synthetic phenotype plays a key role in vascular proliferative syndromes such as atherosclerosis and restenosis. VSMC phenotype switch is associated with alterations of VSMC Ca 2+ handling proteins. Recently, we demonstrated that Ca 2+ cycling in contractile VSMCs requires the expression of the sarco/endoplasmic reticulum Ca 2+ -ATPase (SERCA) isoform SERCA2a. Protein phosphatase inhibitor-1 (I-1), a highly specific inhibitor of protein phosphatase 1, enhances protein kinase A-dependent phospholamban phosphorylation and therefore SERCA2a activity. In the present study, we examined the role of I-1 in the VSMC phenotype switch and the therapeutic potential of constitutively active I-1 (I1c) gene transfer in a postangioplasty restenosis model. In human coronary arteries, we showed that I-1 expression is specific to contractile VSMCs; however, in synthetic VSMCs, I-1 expression was significantly decreased, leading to an increase in its target PP1 and a decrease in phospholamban phosphorylation and SERCA2 activity. In cells coexpressing I-1c and SERCA2a, VSMC proliferation was decreased with an increase in Ca 2+ uptake and sarco/endoplasmic reticulum Ca 2+ load. I-1 knockout mice lack phospholamban phosphorylation and exhibit VSMC arrest in the synthetic state, with a significant modification of contractile properties and relaxant response of femoral artery in vivo and an excessive neointimal proliferation after carotid injury. Local I-1c gene transfer in a rat model of carotid injury decreased neointimal formation by preserving VSMC contractile marker expression and therefore preventing VSMC phenotypic switch. Gene transfer of I1c may be considered a therapeutic strategy for preventing vascular proliferative disorders. See p 773.
Role for DNA Damage Signaling in Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is characterized by progressive pulmonary vascular remodeling. Despite newly developed therapies, most patients eventually develop right ventricular failure and ultimately die. Advances in our understanding of the PAH pathophysiology is thus urgently needed to develop new therapeutic strategies and improve long-term outcomes in this devastating disease. Over the past few years, research in this field has focused on understanding the mechanisms of the enhanced pulmonary artery smooth muscle cell proliferation and suppressed apoptosis accounting for pulmonary vascular remodeling. Many abnormalities contribute to this phenotype, including increased activation of the transcription factors signal transducer and activator of transcription-3, nuclear factor of activated T cells, and hypoxia-inducible factor 1-α , and miR-204 downregulation, as well. In the present study, we demonstrated using a translational approach, that PAH is characterized by significant increase in DNA damage resulting in sustained activation of poly(ADP-ribose) polymerase-1 (PARP-1), a key component of the DNA repair machinery. PARP-1 activation promoted cell survival and proliferation by triggering a miR-204-dependent activation of nuclear factor of activated T cells and hypoxia-inducible factor 1-α, which was reversed by using PARP-1 inhibitors. PARP-1 activation may thus represent a common origin to many abnormalities promoting pulmonary vascular remodeling in PAH. PARP-1 inhibition was not only effective in vivo, but provided even greater efficacy in reversing PAH when combined with currently available therapies. Interestingly, PARP-1 is minimally expressed in the majority of healthy tissues, and phase 2/3 clinical trials investigating PARP-1 inhibitors in cancer are currently ongoing. Consequently, PARP-1 inhibition represents a novel and attractive therapeutic target for PAH. See p 786.
